A number of research firms have changed their ratings and price targets for AMAG Pharmaceuticals (NASDAQ: AMAG):

  • 2/2/2018 – AMAG Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Leerink Swann.
  • 2/2/2018 – AMAG Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 1/29/2018 – AMAG Pharmaceuticals had its “hold” rating reaffirmed by analysts at B. Riley. They now have a $16.00 price target on the stock.
  • 1/24/2018 – AMAG Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/18/2018 – AMAG Pharmaceuticals had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $15.00 price target on the stock.
  • 1/16/2018 – AMAG Pharmaceuticals had its “hold” rating reaffirmed by analysts at B. Riley. They now have a $16.00 price target on the stock.
  • 1/3/2018 – AMAG Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) traded down $0.60 during midday trading on Thursday, hitting $12.30. The company had a trading volume of 1,106,232 shares, compared to its average volume of 919,246. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals, Inc. has a 12 month low of $11.93 and a 12 month high of $25.20. The firm has a market cap of $441.10, a P/E ratio of -2.02 and a beta of 0.79.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.